视神经脊髓炎谱系疾病神经再生研究进展

doi:10.3969/j.issn.1672-6731.2022.09.001

中国现代神经疾病杂志 ›› 2022, Vol. 22 ›› Issue (9): 747-751. doi: 10.3969/j.issn.1672-6731.2022.09.001

2 视神经脊髓炎谱系疾病神经再生研究进展

邱伟¹, 罗文静²

1 510630 广州, 中山大学附属第三医院神经内科;
2 530021 南宁, 广西医学科学院广西壮族自治区人民医院老年神经内科

收稿日期:2022-09-21 出版日期:2022-09-25 发布日期:2022-10-10
通讯作者: 邱伟,Email:qiuwei@mail.sysu.edu.cn
基金资助:
国家自然科学基金资助项目（项目编号：81771300）；国家自然科学基金资助项目（项目编号：81971140）

Research progress of neuroregeneration in neuromyelitis optica spectrum disorders

QIU Wei¹, LUO Wen-jing²

1 Department of Neurology, The Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, Guangdong, China;
2 Department of Geriatric Neurology, Guangxi Academy of Medical Sciences, the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, Guangxi, China

Received:2022-09-21 Online:2022-09-25 Published:2022-10-10
Supported by:
This study was supported by the National Natural Science Foundation of China (No. 81771300, 81971140).

摘要/Abstract

摘要： 神经再生是中枢神经系统疾病治疗的热点和难点，目前对视神经脊髓炎谱系疾病（NMOSDs）神经再生机制的认识相对局限，并缺乏有效治疗方法。本文围绕NMOSDs神经再生的挑战、研究进展和未来研究方向进行综述，以期提高临床对NMOSDs神经再生的认识，为神经再生治疗提供新的思路。

关键词: 视神经脊髓炎, 神经再生, 综述

Abstract: In the treatment of neurological diseases, neuroregeneration is a contentious and challenging issue. Our understanding of the mechanisms related to neuroregeneration in neuromyelitis optica spectrum disorders (NMOSDs) is currently restricted and there lack of effective treatment to promote neuroregeneration and repair. To enhance the knowledge of neuroregeneration in NMOSDs, this article will concentrate on the challenge, current research progress, and future research directions. It will provide suggestions for investigating potential treatments for neuroregeneration in this condition.

Key words: Neuromyelitis optica, Nerve regeneration, Review

邱伟, 罗文静. 视神经脊髓炎谱系疾病神经再生研究进展[J]. 中国现代神经疾病杂志, 2022, 22(9): 747-751.

QIU Wei, LUO Wen-jing. Research progress of neuroregeneration in neuromyelitis optica spectrum disorders[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2022, 22(9): 747-751.

http://journal11.magtechjournal.com/cjcnn/CN/Y2022/V22/I9/747

参考文献

[1] Jarius S, Paul F, Weinshenker BG, Levy M, Kim HJ, Wildemann B.Neuromyelitis optica[J].Nat Rev Dis Primers, 2020, 6:85.
[2] Tian DC, Li Z, Yuan M, Zhang C, Gu H, Wang Y, Shi FD.Incidence of neuromyelitis optica spectrum disorder (NMOSD) in China:a national population-based study[J].Lancet Reg Health West Pac, 2020, 2:100021.
[3] Current status of rare disease NMOSD patients in China:Asian population is more susceptible to the diseaese and it takes an verage of four years to be diagnosed[EB/OL].(2020-05-25)[2022-09-19].https://finance.sina.com.cn/chanjing/cyxw/2020-05-25/doc-iircuyvi4872752.shtml.[中国罕见病NMOSD患者现状:亚洲人群更易感平均四年才能确诊[EB/OL] (.2020-05-25)[2022-09-19].https://finance.sina.com.cn/chanjing/cyxw/2020-05-25/doc-iircuyvi4872752.shtml.]
[4] Nathan FM, Ohtake Y, Wang S, Jiang X, Sami A, Guo H, Zhou FQ, Li S.Upregulating Lin28a promotes axon regeneration in adult mice with optic nerve and spinal cord injury[J].Mol Ther, 2020, 28:1902-1917.
[5] Varadarajan SG, Hunyara JL, Hamilton NR, Kolodkin AL, Huberman AD.Central nervous system regeneration[J].Cell, 2022, 185:77-94.
[6] Horgusluoglu E, Nudelman K, Nho K, Saykin AJ.Adult neurogenesis and neurodegenerative diseases:a systems biology perspective[J].Am J Med Genet B Neuropsychiatr Genet, 2017, 174:93-112.
[7] Elbaz B, Popko B.Molecular control of oligodendrocyte development[J].Trends Neurosci, 2019, 42:263-277.
[8] Kremer D, Göttle P, Hartung HP, Küry P.Pushing forward:remyelination as the new frontier in CNS diseases[J].Trends Neurosci, 2016, 39:246-263.
[9] Liu Y, Given KS, Owens GP, Macklin WB, Bennett JL.Distinct patterns of glia repair and remyelination in antibody-mediated demyelination models of multiple sclerosis and neuromyelitis optica[J].Glia, 2018, 66:2575-2588.
[10] Lubetzki C, Zalc B, Williams A, Stadelmann C, Stankoff B.Remyelination in multiple sclerosis:from basic science to clinical translation[J].Lancet Neurol, 2020, 19:678-688.
[11] Villoslada P, Steinman L.New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis[J].Expert Opin Investig Drugs, 2020, 29:443-459.
[12] Pan S, Chan JR.Clinical applications of myelin plasticity for remyelinating therapies in multiple sclerosis[J].Ann Neurol, 2021, 90:558-567.
[13] Wrzos C, Winkler A, Metz I, Kayser DM, Thal DR, Wegner C, Brück W, Nessler S, Bennett JL, Stadelmann C.Early loss of oligodendrocytes in human and experimental neuromyelitis optica lesions[J].Acta Neuropathol, 2014, 127:523-538.
[14] Lloyd AF, Miron VE.Cellular and molecular mechanisms underpinning macrophage activation during remyelination[J].Front Cell Dev Biol, 2016, 4:60.
[15] Kuhn S, Gritti L, Crooks D, Dombrowski Y.Oligodendrocytes in development, myelin generation and beyond[J].Cells, 2019, 8:1424.
[16] Blakemore WF, Gilson JM, Crang AJ.The presence of astrocytes in areas of demyelination influences remyelination
[17] Liu Y, Given KS, Harlow DE, Matschulat AM, Macklin WB, Bennett JL, Owens GP.Myelin-specific multiple sclerosis antibodies cause complement-dependent oligodendrocyte loss and demyelination[J].Acta Neuropathol Commun, 2017, 5:25.
[18] Tsai HH, Niu J, Munji R, Davalos D, Chang J, Zhang H, Tien AC, Kuo CJ, Chan JR, Daneman R, Fancy SP.Oligodendrocyte precursors migrate along vasculature in the developing nervous system[J].Science, 2016, 351:379-384.
[19] Weber MS, Derfuss T, Metz I, Brück W.Defining distinct features of anti-MOG antibody associated central nervous system demyelination[J].Ther Adv Neurol Disord, 2018, 11:1756286418762083.
[20] Yao X, Su T, Verkman AS.Clobetasol promotes remyelination in a mouse model of neuromyelitis optica[J].Acta Neuropathol Commun, 2016, 4:42.
[21] Tradtrantip L, Asavapanumas N, Verkman AS.Emerging therapeutic targets for neuromyelitis optica spectrum disorder[J].Expert Opin Ther Targets, 2020, 24:219-229.
[22] Luo W, Xu H, Xu L, Jiang W, Chen C, Chang Y, Liu C, Tian Z, Qiu X, Xie C, Li X, Chen H, Lai S, Wu L, Cui Y, Tang C, Qiu W.Remyelination in neuromyelitis optica spectrum disorder is promoted by edaravone through mTORC1 signaling activation[J].Glia, 2022.[Epub ahead of print]
[23] Rodney C, Rodney S, Millis RM.Vitamin D and demyelinating diseases:neuromyelitis optica (NMO) and multiple sclerosis (MS)[J].Autoimmune Dis, 2020:ID8718736.
[24] Derdelinckx J, Reynders T, Wens I, Cools N, Willekens B.Cells to the rescue:emerging cell-based treatment approaches for NMOSD and MOGAD[J].Int J Mol Sci, 2021, 22:7925.
[25] Hoay KY, Ratnagopal P.Autologous hematopoietic stem cell transplantation for the treatment of neuromyelitis optica in Singapore[J].Acta Neurol Taiwan, 2018, 27:26-32.J, Jovanovic
[26] Burt RK, Balabanov R, Han X, Burns C, Gastala B, Helenowski I, Jitprapaikulsan J, Fryer JP, Pittock SJ.Autologous nonmyeloablative hematopoietic stem cell transplantation for neuromyelitis optica[J].Neurology, 2019, 93:e1732-1741.
[27] Lu Z, Zhu L, Liu Z, Wu J, Xu Y, Zhang CJ.IV/IT hUC-MSCs infusion in RRMS and NMO:a 10-year follow-up study[J].Front Neurol, 2020, 11:967.
[28] Fu Y, Yan Y, Qi Y, Yang L, Li T, Zhang N, Yu C, Su L, Zhang R, Shen Y, Lin S, Liu Q, Shao Z, Han Z, Shi FD.Impact of autologous mesenchymal stem cell infusion on neuromyelitis optica spectrum disorder:a pilot, 2-year observational study[J].CNS Neurosci Ther, 2016, 22:677-685.
[29] Anderson MA, O'Shea TM, Burda JE, Ao Y, Barlatey SL, Bernstein AM, Kim JH, James ND, Rogers A, Kato B, Wollenberg AL, Kawaguchi R, Coppola G, Wang C, Deming TJ, He Z, Courtine G, Sofroniew MV.Required growth facilitators propel axon regeneration across complete spinal cord injury[J].Nature, 2018, 561:396-400.
[30] Herwerth M, Kenet S, Schifferer M, Winkler A, Weber M, Snaidero N, Wang M, Lohrberg M, Bennett JL, Stadelmann C, Hemmer B, Misgeld T.A new form of axonal pathology in a spinal model of neuromyelitis optica[J].Brain, 2022, 145:1726-1742.multiple
[31] Kawachi I, Lassmann H.Neurodegeneration in sclerosis and neuromyelitis optica[J].J Neurol Neurosurg Psychiatry, 2017, 88:137-145.
[32] Schattling B, Steinbach K, Thies E, Kruse M, Menigoz A, Ufer F, Flockerzi V, Brück W, Pongs O, Vennekens R, Kneussel M, Freichel M, Merkler D, Friese MA.TRPM4 cation channel mediates axonal and neuronal degeneration in experimental autoimmune encephalomyelitis and multiple sclerosis[J].Nat Med, 2012, 18:1805-1811.
[33] Giaume C, Leybaert L, Naus CC, Sáez JC.Connexin and pannexin hemichannels in brain glial cells:properties, pharmacology, and roles[J].Front Pharmacol, 2013, 4:88.
[34] Masaki K, Suzuki SO, Matsushita T, Matsuoka T, Imamura S, Yamasaki R, Suzuki M, Suenaga T, Iwaki T, Kira J.Connexin 43 astrocytopathy linked to rapidly progressive multiple sclerosis and neuromyelitis optica[J].PLoS One, 2013, 8:e72919.
[35] May D, Tress O, Seifert G, Willecke K.Connexin 47 protein phosphorylation and stability in oligodendrocytes depend on expression of connexin 43 protein in astrocytes[J].J Neurosci, 2013, 33:7985-7996.
[36] Orellana JA, Froger N, Ezan P, Jiang JX, Bennett MV, Naus CC, Giaume C, Sáez JC.ATP and glutamate released via astroglial connexin 43 hemichannels mediate neuronal death through activation of pannexin 1 hemichannels[J].J Neurochem, 2011, 118:826-840.S, Ransom BR.Functional
[37] Ye ZC, Wyeth MS, Baltan-Tekkok hemichannels in astrocytes:a novel mechanism of glutamate release[J].J Neurosci, 2003, 23:3588-3596.
[38] Richard C, Ruiz A, Cavagna S, Bigotte M, Vukusic S, Masaki K, Suenaga T, Kira JI, Giraudon P, Marignier R.Connexins in neuromyelitis optica:a link between astrocytopathy and demyelination[J].Brain, 2020, 143:2721-2732.

选择文件类型/文献管理软件名称

选择包含的内容

2 视神经脊髓炎谱系疾病神经再生研究进展

Research progress of neuroregeneration in neuromyelitis optica spectrum disorders

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	薛蓉, 张轩. 睡眠障碍对脑血管病的影响[J]. 中国现代神经疾病杂志, 2023, 23(8): 659-662.
[2]	张鹏, 陈涛, 许莉. 成人失眠认知行为疗法关键技术与流程改进建议[J]. 中国现代神经疾病杂志, 2023, 23(8): 663-667.
[3]	张轩, 薛蓉. 特发性快速眼动睡眠期行为障碍向神经系统变性疾病转化的生物学标志物研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 668-673.
[4]	刘引, 汤永红, 翟锦霞, 邱媛. 慢性低度炎症与睡眠障碍研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 674-677.
[5]	于洁洋, 张亚男, 李惠敏, 黄真灿, 李宛儒, 王赞. 发作性睡病与焦虑研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 678-682.
[6]	库成心, 邓丽影, 谢亮. 缺血性卒中继发日间过度思睡研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 683-686.
[7]	姜佳凤, 赵莲花, 赵伟. 褪黑素在阿尔茨海默病病理损害机制中的作用[J]. 中国现代神经疾病杂志, 2023, 23(8): 687-692.
[8]	黄沛, 王刚. 功能性帕金森综合征诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(8): 738-741.
[9]	洪涛, 唐斌. 如何成为一名优秀的颅底外科医师[J]. 中国现代神经疾病杂志, 2023, 23(7): 571-574.
[10]	张庆硕, 宋丹丹, 周世越, 张金璐, 韩晓旭, 许顺良. 功能性步态障碍诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(7): 604-609.
[11]	潘希娟, 邢英琦, 刘玉梅. 脑小血管病影像学评分方法[J]. 中国现代神经疾病杂志, 2023, 23(7): 633-637.
[12]	俞淑凤, 李宁, 徐健, 王鹏. 颈动脉漂浮血栓相关缺血性卒中诊断与治疗进展[J]. 中国现代神经疾病杂志, 2023, 23(7): 638-642.
[13]	魏俊吉. 神经外科重症医学规范化诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(6): 477-478.
[14]	杜倩, 邓素君, 邹姗, 金珺, 周青山. 宏基因组第二代测序技术在重症中枢神经系统感染中的应用[J]. 中国现代神经疾病杂志, 2023, 23(6): 479-484.
[15]	曲鑫, 赵浩, 尚峰, 王宁. 神经重症目标温度管理[J]. 中国现代神经疾病杂志, 2023, 23(6): 485-489.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

2 视神经脊髓炎谱系疾病神经再生研究进展

Research progress of neuroregeneration in neuromyelitis optica spectrum disorders

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价